Insulet stock falls 3.89% and underperforms rivals
Updated
Updated · MarketWatch · May 8
Insulet stock falls 3.89% and underperforms rivals
9 articles · Updated · MarketWatch · May 8
Shares closed at $154.16 as the S&P 500 rose 0.84% to 7,398.93 and the Dow Jones Industrial Average edged up 0.02% to 49,609.16.
Insulet lagged Eli Lilly, down 2.72%, DexCom, down 0.49%, and Johnson & Johnson, down 0.53%, despite a broadly positive market session.
The stock finished 56.56% below its 52-week high of $354.88 reached on 20 November, while trading volume of 1.7 million topped its 50-day average of 1.2 million.
With record sales clashing with a severe FDA recall, is Insulet's beaten-down stock a huge opportunity or a trap?
Can Insulet's future innovations rebuild patient trust after its flagship insulin pump was deemed life-threatening by the FDA?